Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Publication year range
1.
Ann Endocrinol (Paris) ; 53(5-6): 201-7, 1992.
Article in French | MEDLINE | ID: mdl-1364120

ABSTRACT

Two brothers and a sister with acromegaly--one of them with acromegalogigantism--are described. They all presented pituitary adenomas, and the diagnosis was made between the ages of 17 and 29. There was no feature of multiple endocrine neoplasia. The familial investigation consisted of detailed interrogation, basal hormonal evaluation and HLA determination (haplotypes A and B) in 14 members, including the patients themselves. Despite basal plasma GH levels ranging from 8.00 to 10.00 ng/ml in 3 other family members, the normality of both GH response to induced-hyperglycemia and CT-imaging of the pituitary gland excluded the diagnosis of acromegaly in these subjects. No correlation with the HLA haplotypes was observed. Differential diagnosis with familial multiple endocrine neoplasia (MEN type 1) is discussed. Previous reports of familial acromegaly are reviewed and analysed. It appears that familial acromegaly may be considered as a specific entity for two main reasons: 1) owing to the low incidence of acromegaly in the general population, familial cases are unlikely to be fortuitous. 2) most of the reported cases share some common clinical features, such as a male predominance, a high incidence of acromegalogigantism, and the presence of a pituitary macroadenoma. However, the primitive disorder and the genetic transmission of the disease are still unknown.


Subject(s)
Acromegaly/genetics , Acromegaly/blood , Acromegaly/diagnosis , Acromegaly/immunology , Adolescent , Adult , Diagnosis, Differential , Female , HLA-A Antigens/genetics , HLA-B Antigens/genetics , Haplotypes , Humans , Male , Multiple Endocrine Neoplasia/diagnosis , Pituitary Hormones/blood
2.
Minerva Endocrinol ; 14(4): 213-9, 1989.
Article in Italian | MEDLINE | ID: mdl-2561518

ABSTRACT

Fourteen patients with pituitary lesions and 6 normal subjects underwent the following tests: a) LHRH (100 mcg) + TRH (200 mcg) + Human Insulin (0.1 UI/kg) i.v. (Politest "A"); b) LHRH (100 mcg) + TRH (200 mcg) + GHRH 1-29NH2 (100 mcg) i.v. (Politest "B"); c) GHRH 1-29NH2 (100 mcg) i.v. (GHRH-TEST). FSH, LH and PRL, as assayed in patients and controls in response to Politest "A" and "B", revealed no significant differences between the tests. Plasma TSH values were significantly higher after Politest "B" in both patients and normals. The GH response after Politest "A" and "B" was similar in magnitude and concordant in 88.8% of cases.


Subject(s)
Adenoma/physiopathology , Gonadotropin-Releasing Hormone , Growth Hormone-Releasing Hormone/analogs & derivatives , Peptide Fragments , Pituitary Neoplasms/physiopathology , Thyrotropin-Releasing Hormone , Adult , Female , Follicle Stimulating Hormone/metabolism , Gonadotropin-Releasing Hormone/administration & dosage , Growth Hormone/metabolism , Growth Hormone-Releasing Hormone/administration & dosage , Humans , Hydrocortisone/metabolism , Infusions, Intravenous , Insulin/administration & dosage , Luteinizing Hormone/metabolism , Male , Middle Aged , Peptide Fragments/administration & dosage , Pituitary Function Tests , Prolactin/metabolism , Random Allocation , Sermorelin , Thyrotropin/metabolism , Thyrotropin-Releasing Hormone/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL